The purpose of this study is to determine whether very low birth weight infants (less than or equal to 1250g or about 2 3/4 pounds) born prematurely fed a diet of only human milk and human milk-derived nutrition have better health outcomes than babies fed at least some formula (made from cow's milk)or formula-derived nutrition.
The goal of this study is to evaluate the short-term effect (up to 90 days of life) of purely human-based nutrition using mother's own milk (when available), donor milk preparations and a human-based fortifier (Prolact+4) as needed when compared with mother's own milk supplemented with pre-term formula and using a bovine-based HMF (as needed for fortification of mother's own milk), i.e. "Study Group 1"; or, when mother's milk is not available, comparing the use of donor milk (plus human milk based fortification) with pre-term/term formula, i.e. "Study Group 2". In both instances the comparison will be based on the primary endpoint of days of TPN, and on parameters such as time to full enteral feeding (approximately 150-160 mL/kg/day), amount of IV fluid support, culture-proven sepsis, NEC, death, growth and short-term development, cultured-proven sepsis and incidence of feeding intolerance in either a 2-arm (human nutrition versus bovine nutrition: "Study Group 2") or 3-arm randomized design (human fortifier given when feedings reach 40 mL/kg/day, human fortifier given when feedings reach 100 mL/kg/day, and bovine-based HMF given when feedings reach 100 mL/kg/day \[or pre-term formula if mother's milk is not available\]: "Study Group 1"). Statistically, the study will attempt to evaluate a null hypothesis of equivalent results with respect to these parameters between either the three types of fortifications in "Study Group 1" or the two types of overall nutrition in "Study Group 2", as compared with an alternative of some inequality between the groups, i.e. letting μ be the mean number of days of TPN any of the study arms, then for "Study Group 1 the hypotheses may be written as: H0: μ control = μ human 40 = μhuman 100 and HA: At least two of μ control, μ human 40, and μhuman 100 are not equal, where "control" is the bovine-based HMF group, "human 40" is the human fortifier group starting at 40 mL/kg/day (arm 2) and "human 100" is the human fortifier group starting at 100 mL/kg/day (arm 1). For "Study Group 2", the competing hypotheses are: H0: μ formula = μ human and HA: μ formula ≠ μ human , where "formula" is the pre-term/term formula group and "human" is the human-based (donor milk/human-based fortifier) group. In addition, data will be collected on overall survival and length of stay in the NICU. Any baby that does not complete the full study period will be right-censored in this regard for the purposes of data evaluation. For centers that obtain long-term follow up (18-24 months) on their patients, data on developmental outcomes will be evaluated as available.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Enrollment
260
Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
Alta Bates Summit Medical Center
Berkeley, California, United States
University of California, San Diego Medical Center
San Diego, California, United States
Yale University School of Medicine
The primary measure of efficacy for the study is the number of days of TPN (total parenteral nutrition)
Time frame: The first 90 days of life, discharge from the study institution or initiation of 50% oral nutrition (50% of the feeding volume in a given 24 hour period provided PO, or 4 complete PO feeds in a given 24 hour period), whichever comes first
Weight gain and other measures of growth including length and head circumference
Time frame: The first 90 days of life, transfer to non-study institution, or initiation of 50% oral feeding, whichever comes first
Daily amount of all nutrition
Time frame: The first 90 days of life, transfer to non-study institution, or initiation of 50% oral feeding, whichever comes first
Time to discharge from the NICU and hospital
Time frame: The first 90 days of life, transfer to non-study institution, or initiation of 50% oral feeding, whichever comes first
Frequency of occurrence of late-onset sepsis and necrotizing enterocolitis
Time frame: The first 90 days of life, transfer to non-study institution, or initiation of 50% oral feeding, whichever comes first
Frequency of feeding intolerance
Time frame: The first 90 days of life, transfer to non-study institution, or initiation of 50% oral feeding, whichever comes first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
Bovine milk-derived nutrition formulated for very low birth weight infants
New Haven, Connecticut, United States
Shands Children's Hospital
Gainesville, Florida, United States
Rush-Presbyterian St. Luke's Medical Center
Chicago, Illinois, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Schneider Children's Hospital at North Shore
Manhasset, New York, United States
Strong Memorial Hospital
Rochester, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Ben Taub Hospital/Baylor College of Medicine
Houston, Texas, United States
...and 3 more locations